Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00150813
Status:
COMPLETED
Last Update Posted:
2018-11-21
First Post:
2005-09-06
Brief Title:
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy
Sponsor:
UCB Pharma SA
Organization:
UCB Pharma
Study Overview
Official Title:
A Multicenter Open-label Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mgDay Oral Tablets of 500 mg bid Used as Monotherapy in Subjects 16 Years Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None